Why a universal antiretroviral regimen?

The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen

PURPOSE OF REVIEW Current WHO-recommended first-line therapy in low-income and middle-income countries has been very successful in saving millions of lives but still has toxicity concerns and a low barrier to resistance. RECENT FINDINGS Two candidate antiretrovirals may substantially transform first-line therapy in low-income and middle-income countries, yielding a safer, more robust and chea...

Antiretroviral-Chemotherapy Interactions: ABVD Regimen

Laboratory interactions (Quality of Evidence: high; no clinical significance) • Cobicistat (Stribild®, Tybost®), rilpivirine (Edurant®, Complera®) and dolutegravir (Tivicay®) containing regimens will increase serum creatinine by approximately 7-15 μmol/L during the first 4 weeks of treatment initiation due to inhibition of renal creatinine secretion. This does not reflect an actual decrease in ...

Antiretroviral regimen complexity as a predictor of adherence

Purpose of study Even with the introduction of once daily antiretroviral (ARV) regimens of low pill burden, long-term adherence remains a challenge, particularly in subgroups, such as patients with drug addiction. We aimed to determine levels of adherence and identify factors associated with suboptimal adherence in treated, HIV-infected patients attending a busy European inner-city HIV outpatie...

Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study.

In a cohort of 128 human immunodeficiency virus-infected patients, we found that patients' knowledge of antiretroviral dosing was suboptimal at regimen initiation but improved with time. Poor medication knowledge 8 weeks after regimen initiation was associated with lower adherence and with a lower level of literacy in a multivariate model (P=.03). Because knowledge deficits are common after ant...

Mani and shapur a universal faith for e universal kingdom